GlassScriptPhysician profile
Abraham R Byrd
NPI 1669430385
$3,733.45
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $299 · 2021: $533 · 2022: $1,216 · 2023: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $535.90 | 2019-2023 | Fasenra |
| Glaxosmithkline, LLC. | $485.08 | 2019-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Novo Nordisk INC | $256.70 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $239.00 | 2020-2023 | |
| Amgen INC. | $229.72 | 2019-2023 | Prolia, Evenity, Otezla |
| Lilly USA, LLC | $209.64 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Abbott Laboratories | $196.70 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $182.89 | 2019-2023 | |
| Abbvie INC. | $168.17 | 2019-2023 | Linzess, Viberzi, Creon |
| Merck Sharp & Dohme LLC | $138.86 | 2019-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.43 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $113.22 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $106.03 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.17 | 2019-2023 | Trulance, Xifaxan |
| Nestle Healthcare Nutrition INC. | $72.83 | 2022-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.29 | 2019-2023 | |
| Radius Health, INC. | $54.77 | 2019-2023 | Tymlos |
| Bard Peripheral Vascular, INC. | $48.76 | 2022 | |
| Xeris Pharmaceuticals, INC. | $38.59 | 2023 | Recorlev |
| Nevro Corp. | $33.13 | 2023 | Senza |
| Amneal Pharmaceuticals LLC | $30.92 | 2022-2023 | Unithroid |
| Sanofi Pasteur INC. | $29.85 | 2020-2023 | |
| Scilex Pharmaceuticals INC. | $28.74 | 2019-2020 | |
| Gilead Sciences, INC. | $28.06 | 2021 | |
| Embecta Corp. | $24.29 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Bayer Healthcare Pharmaceuticals INC. | $21.38 | 2022 | |
| Eisai INC. | $19.68 | 2022 | |
| Seqirus USA INC | $19.08 | 2022 | |
| Exact Sciences Corporation | $18.97 | 2023 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $18.57 | 2022 | |
| Allergan, INC. | $18.03 | 2020 | |
| Tandem Diabetes Care, INC. | $17.60 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.00 | 2022 | |
| Phadia US INC. | $16.55 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.41 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.30 | 2023 | Quviviq |
| Astellas Pharma US INC | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.